trending Market Intelligence /marketintelligence/en/news-insights/trending/VLujxhInLKv9dKEFUWmFvQ2 content esgSubNav
In This List

Silence Therapeutics sues Alnylam, Medicines Co. in UK High Court

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints


Silence Therapeutics sues Alnylam, Medicines Co. in UK High Court

Silence Therapeutics plc filed a claim against Alnylam Pharmaceuticals Inc. and The Medicines Co. in the UK High Court to enforce its intellectual property rights on certain Alnylam products.

The claim asks the court to determine whether Silence is entitled to supplementary protection certificates over products including drugs Patisiran, Fitusiran, Givosiran and Inclisiran.

Supplementary protection certificates are intellectual property rights which can give up to five years of exclusivity after a patent expires.

Alnylam and Medicines Co. are jointly developing cholesterol-lowering drug Inclisiran. A phase 3 trial of Patisiran in treating a rare nerve disorder familial amyloid polyneuropathy recently met its main goal.

Fitusiran and Givosiran are early state drugs being developed for treating hemophilia and acute hepatic porphyrias, respectively.